Annual report pursuant to Section 13 and 15(d)

Acquisition of Ceregene - Additional Information (Detail)

v3.6.0.2
Acquisition of Ceregene - Additional Information (Detail)
1 Months Ended 12 Months Ended
Oct. 31, 2013
USD ($)
shares
Dec. 31, 2015
USD ($)
Dec. 31, 2016
USD ($)
Candidate
Mar. 31, 2015
USD ($)
Business Acquisition [Line Items]        
Impairment charge   $ 1,870,000    
Goodwill   1,585,000 $ 1,585,000  
Ceregene, Inc. [Member]        
Business Acquisition [Line Items]        
Common stock, transferred, shares | shares 100,000      
Sangamo shares of common stock $ 1,200,000      
Contingent earn-out 1,500,000      
Fair value of contingent earn-out liability 1,800,000     $ 0
Number of clinical product candidates | Candidate     2  
Estimated fair values of in-process research and development 1,900,000      
Impairment charge   $ 1,900,000    
Goodwill $ 1,600,000